The Breast Cancer Program at the University of Southern California (USC)/Norris Comprehensive Cancer Center (NCC) is a focused interdisciplinary research program devoted to breast cancer. The scientific aims of the program are 1) to Test hypotheses of breast cancer etiology and pathogenesis with a particular emphasis on diverse racial/ethnic groups within Los Angeles County, 2) To identify differences in breast cancer mortality among racial ethnic groups of Los Angeles County and formulate strategies to lower mortality among all groups. 3) To characterize molecular genetic alterations in breast cancers with a focus on potential clinical utility, 4) To formulate and assess various strategies for breast cancer prevention, and 5) To develop and/or evaluate novel therapies for breast cancer; to enroll patients on local or national therapeutic protocols related to breast cancer, particularly emphasizing minority patient recruitment. The USC/Norris Breast Cancer Program takes advantage of the extraordinary, racial-ethic diversity among the 10 million residents of Los Angeles County, the population served by the NCCC. A major goal of the Program is to better understand the reasons for the underlying differences in breast cancer incidence, mortality and survival among the numerically most important of these racial-ethnic groups in the County (African-Americans, Latinas, Japanese, Chinese, Filipinas, Koreans and non-Latina whites). We have a multifaceted approach involving epidemiology and prevention scientists, behavioral scientists, tumor biologists and molecular geneticists, and radiation surgical and medical oncologists. Numerous patient and data resources are used to achieve this goal. These include the Los Angeles County SEER cancer registry program; a registry of breast cancer in twins; dietary and lifestyle data from recently characterized large racial- ethnically diverse cohorts; a large and diverse clinical population seen at NCCC affiliated hospitals; and several large tumor and other biological sample banks for studies of tumor biology and molecular genetics. The integrated multi-disciplinary Lee Breast Center has been built in the Hospital providing an environment favorable to patient care and clinical research. Recruitment of study subjects to clinical investigations has been strengthened during the last funding period. The overall annual research budget for the Program is in excess of $7 million. Four members of the Breast Cancer Program have been named to endowed Chairs in the NCCC. Funding has been provided for recruitment of new faculty, an annual program retreat, pilot research projects, and startup research funds for recruited faculty.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-27
Application #
6563678
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2001-12-01
Project End
2002-11-30
Budget Start
Budget End
Support Year
27
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Liu, Minmin; Zhang, Lian; Li, Hongtao et al. (2018) Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 68:1412-1428
Miller, Kimberly A; Ramirez, Cynthia N; Wojcik, Katherine Y et al. (2018) Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. Support Care Cancer 26:1305-1313
Belic, Jelena; Graf, Ricarda; Bauernhofer, Thomas et al. (2018) Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer 143:1236-1248
Tobin, Jessica; Allem, Jon-Patrick; Slaughter, Rhona et al. (2018) Posttraumatic growth among childhood cancer survivors: Associations with ethnicity, acculturation, and religious service attendance. J Psychosoc Oncol 36:175-188
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472

Showing the most recent 10 out of 842 publications